Research Papers:

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib

Hiroyuki Arai, Kunihisa Miyakawa, Tadamichi Denda, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa and Takako Eguchi Nakajima _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:110530-110539. https://doi.org/10.18632/oncotarget.22807

Metrics: PDF 1405 views  |   HTML 1938 views  |   ?  


Hiroyuki Arai1, Kunihisa Miyakawa2, Tadamichi Denda3, Takuro Mizukami1, Yoshiki Horie1, Naoki Izawa1, Mami Hirakawa1, Takashi Ogura1, Takashi Tsuda1, Yu Sunakawa1 and Takako Eguchi Nakajima1

1Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan

2Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan

3Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan

Correspondence to:

Takako Eguchi Nakajima, email: [email protected]

Keywords: colorectal cancer; regorafenib; morphological change; liver metastasis; lung metastasis

Received: September 18, 2017     Accepted: November 13, 2017     Published: November 30, 2017


Background and Objective:It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib.

Results: This study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). The median progression-free survival (PFS) and overall survival (OS) in patients with/without CF were 4.2/2.4 months (p<0.01) and 9.2/6.5 months (p=0.09), respectively. Among 45 patients with liver metastasis, 14 (31%) had active morphological response (MR). The median PFS and OS in patients with/without active MR were 5.3/2.4 months (p<0.01) and 13.6/6.9 months (p=0.02), respectively. Overall, 25 patients (37%) had EMC. The median PFS and OS in patients with/without EMC were 5.3/2.1 months (p<0.01) and 13.3/6.1 months (p<0.01), respectively.

Materials and Methods: This retrospective study included mCRC patients with lung and/or liver metastases receiving regorafenib. CF in lung metastasis and MR in liver metastasis were evaluated at the first post-treatment computed tomography scan. EMC was determined as CF and/or active MR. We compared PFS and OS between patients with and those without EMC.

Conclusions: EMC could be a useful predictive marker for regorafenib in mCRC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22807